Cell Biotech Co

Cell Biotech Co DSCR

The Debt Service Coverage Ratio (DSCR) of Cell Biotech Co (049960.KQ) as of Oct 17, 2026 is 52.55. In the previous year, Debt Service Coverage Ratio (DSCR) was 8.37 — a change of 528.09% (higher).

DSCR

52.55

YoY

528.09%

Last updated:

Debt Service Coverage Ratio (DSCR) of Cell Biotech Co is 2024 52.55 . Debt Service Coverage Ratio (DSCR) of Cell Biotech Co was 2023 8.37 . It decreases by 528.09% higher compared to the previous year.

The Cell Biotech Co DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2019
19.98 KRW
Jan 1, 2020
13.93 KRW
Jan 1, 2021
35.17 KRW
Jan 1, 2022
35.81 KRW
Jan 1, 2023
8.37 KRW
Jan 1, 2024
52.55 KRW
The Cell Biotech Co DSCR history
YEARDSCRYoY
52.55+528.09%
8.37-76.64%
35.81+1.84%
35.17+152.40%
13.93-30.26%
19.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co Ltd is a South Korean company based in Gimpo, Gyeonggi-Do, operating within the Health Care sector, specifically in the Biotechnology industry. The company went public through an IPO on December 13, 2002. Its primary focus is on the research, development, and manufacturing of probiotics, particularly lactobacillus-based products. Cell Biotech produces lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines aimed at enhancing immunity and improving digestion. Additionally, the company develops finished products containing LABs, designed for applications such as intestinal health improvement, carcinogen inhibition, and calcium supplementation. These products are distributed both domestically within South Korea and internationally. The company's website is http://www.cellbiotech.com/, providing further information about its operations and offerings. Cell Biotech's activities are centered around biotechnology solutions that support health and wellness through probiotic applications. The firm operates with a focus on research and development to advance its product lines, though specific details about its research initiatives or product names beyond the mentioned categories are not provided. The company's market presence spans both domestic and international channels, reflecting its commitment to delivering probiotic-based health solutions across various markets. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Debt Service Coverage Ratio (DSCR) of Cell Biotech Co is 52.55 in 2024.

Debt Service Coverage Ratio (DSCR) of Cell Biotech Co changed from 8.37 to 52.55, representing a 528.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cell Biotech Co

All Key Metrics — Cell Biotech Co